


Verseau Therapeutics

Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. With a proprietary all-human translational system Verseau identifies novel targets and develops therapies that shift macrophages between immune activators and silencers in disease. Verseau's data suggest that the patient population benefitting from immunotherapy can be at least doubled. The company's initial focus is building a pipeline of first-in-class therapies that modulate macrophages to trigger a coordinated immune attack on cancer.

Macrophage Checkpoint Modulators

Verseau is broadening the therapeutic potential of immunotherapy by developing macrophage checkpoint modulators (MCMs) that regulate the functional shift to make macrophages more inflammatory or more tolerogenic depending on the disease context. While PD-1 inhibitors have provided great clinical successes, they are only effective in 10-15% of cancer patients. Macrophages demonstrate one of the highest infiltration rates in human tumors (~75%*). MCMs cause tumors to turn highly inflammatory and stimulate multiple immune cell types, including T cells. Verseau's therapies have the potential to significantly expand the number of patients benefitting from immunotherapy, including those unresponsive to PD-1 inhibitor therapies.



Founded
in 2017

Multiple validated
novel targets

Validated targets amenable to
monoclonal antibodies, small
molecules and nucleic acid

Applicability in
cancer, immune and
inflammatory diseases

The Verseau Platform

Verseau is developing a pipeline of potential first-in-class antibody therapies with an initial focus in cancer and follow-on programs in conditions with excessive inflammation. The Company utilizes its deep myeloid cell knowledge and advanced computational biology capabilities to identify novel macrophage checkpoints and employ its proprietary siRNA reagents and delivery technology to validate targets in primary human cells. Through its proprietary all-human translational system Verseau has validated more than two dozen targets amenable to different therapeutic modalities, including monoclonal antibodies (mAbs).

Macrophage Targeting Immunotherapies

In patient derived primary tumors, several of Verseau's macrophage checkpoint modulators (MCMs) are shown to induce tumor microenvironment activation, T cell activation and naïve immune cell recruitment amounting to a coordinated immune attack. This activity is seen when Verseau's MCMs are engaged as a monotherapy in both PD-1 responders and non-responders. The MCMs also demonstrate additivity to PD-1 inhibition. Verseau has several ongoing mAb programs and anticipates advancing into IND-enabling studies in the near term. Verseau is diligently working to bring these potential therapies to patients who are not currently seeing enough or any benefit from immunotherapy.

*Proprietary Genomic Analysis by Verseau: 10,000 cancer patients across 33 tumor types

Investors

20/20 HealthCare Partners
3SBio

Alexandria Venture Investments
Highlight Capital

InHarv Partners
The Mark Foundation
Yonghua Capital

Team

Executive Team

Christine Bunt, Ph.D.
Chief Executive Officer and
Chairman of the Board

Robert Crane, MBA
Chief Financial Officer

Igor Feldman, Ph.D.
Co-Founder and Head of
Computational Biology

Tatiana Novobrantseva, Ph.D.
Co-Founder and
Chief Scientific Officer

Board of Directors

Christine Bunt, Ph.D.
Chief Executive Officer and
Chairman, Verseau

Dan Anderson, Ph.D.
Co-Founder, Verseau
Professor, Applied Biology, Koch
Institute, MIT

Jong Chang, MBA
Founder & Chairman, InHarv
Partners

Wen Chen, MBA
Senior Vice President, Tigermed
Co. Ltd.

Bob Langer, Ph.D.
Co-Founder, Verseau
David H. Koch Professor, Koch
Institute, MIT

Zhenping Zhu, M.D., Ph.D.
President of Research &
Development, Chief Scientific
Officer, 3SBio Inc.

Advisors

Antoine Awad
Senior Advisor, Verseau
Head of Technical Operations,
Synlogic Therapeutics

George Golumbeski, Ph.D.
Senior Advisor, Verseau
President, Head of Corporate
Development and Strategy, Grail